Mon Sep 09 16:12:00 UTC 2024: ## CVS Health Corporation Sued for Misleading Investors, Lead Plaintiff Deadline Approaching

**New York, NY (September 9, 2024) –** The Rosen Law Firm, a prominent investor rights firm, is reminding shareholders of CVS Health Corporation (NYSE: CVS) who purchased securities between February 9, 2022 and April 30, 2024 of the upcoming lead plaintiff deadline on September 10, 2024.

The lawsuit alleges that CVS misled investors by failing to disclose its deficient internal controls and the inaccurate financial information they generated. Specifically, the suit claims that CVS’s financial statements for fiscal year 2022 contained false information regarding the profitability of its Health Care Benefits segment. This, the lawsuit argues, resulted in investors suffering damages when the truth came to light.

Investors who purchased CVS securities during the specified period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement. Interested parties are encouraged to visit the Rosen Law Firm’s website or contact Phillip Kim, Esq. for more information on joining the class action.

The deadline for potential lead plaintiffs to move the court is September 10, 2024. A lead plaintiff is a representative party who directs the litigation on behalf of other class members. The Rosen Law Firm encourages investors to select qualified counsel with a proven track record of success in this area.

The Rosen Law Firm is a globally recognized firm with extensive experience in securities class actions and shareholder derivative litigation. The firm has achieved significant settlements for investors, including the largest ever securities class action settlement against a Chinese company.

**Please note that no class has been certified. Until certification occurs, you are not represented by counsel unless you retain one. You may also choose to remain an absent class member and take no action at this time.**

For updates on this case, follow the Rosen Law Firm on LinkedIn, Twitter, or Facebook.

Read More